MDROR-NetNCT04937361
Monitoring of MDRO Dynamics and Resistance Mechanisms in a University Hospital Network
An observational study of MDRO, run by University of Luebeck at 1 site in Germany.
Trial summary
Survey on the prevalence of MDRO to monitor the import of MDRO from the community. Rectal swabs will be taken and cultivated. Survey on community-onset and nosocomial bloodstream infections will be documented and strains will be isolated. For each BSI a clinical data set will be obtained (e.g. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- MDRO
- What is being tested?
- rectal swab
- How many people
- 14,607 participants
- Where
- 1 siteGermany
- Study dates
- 23 Jun 2021to 31 May 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: For the prevalence, adult patients admitted to the hosptial within the last 3 days. For BSI surveillance, adult inpatients with at least one blood culture positive for any of the target organisms: Staphylococcus aureus, Enterococcus spp., Escherichia coli, Enterobacter spp., Klebsiella spp., Acinetobacter baumannii, Pseudomonas aeruginosa.
Who may be able to join
- at least 18 years old
- informed consent
- inpatient
Who cannot join
- less than 18 years old
- Not capable of giving informed consent
- outpatient
Trial locations and contacts
1 site in 1 country.
About this study
Survey on the prevalence of MDRO to monitor the import of MDRO from the community. Rectal swabs will be taken and cultivated. Survey on community-onset and nosocomial bloodstream infections will be documented and strains will be isolated. For each BSI a clinical data set will be obtained (e.g. patient age, gender, date of hospitalization, antibiotic therapy). Genetic analysis of MDRO from the prevalence and BSI study. In a subset of patients the microbiome-resistome interactome will be analysed in more detail. Furthermore, the impact of infection control measures due to the Covid-19 pandemic on nosocomial BSI will be investigated.
- Conditions
- MDRO
- Being tested
- rectal swab
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
rectal swabOther
collection of rectal swabs
What is being measured
The primary outcome is the main question the study is designed to answer.
monitoring of MDRO prevalence
obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure
Measured: at hospital admission
monitoring of blood stream infections
obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure
Measured: during hospitalization, up to 4 weeks
integrate novel techniques for microbiome-resistome interaction analysis
obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure
Measured: through study completion, after 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2021
- Study start23 Jun 2021
- Primary completion28 Feb 2025
- Study completion31 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MDROStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 14,607 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- University of Luebeck
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital of Berlin, University Hospital of Cologne, University Hospital Freiburg, University of Giessen, University Hospital Tuebingen
- Responsible party
- Principal investigator, Nadja Käding, University of Luebeck
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04937361
- Sponsor's protocol ID
- DZIF TTU 08.824
- Acronym
- R-Net
- Status last verified
- Apr 2026
- First submitted
- 10 Jun 2021
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Monitoring of MDRO Dynamics and Resistance Mechanisms in a University Hospital Network
- ClinicalTrials.gov ID
- NCT04937361
- Acronym / sponsor ID
- R-Net / DZIF TTU 08.824
- Conditions
- MDRO
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 14,607 participants (actual)
- Lead sponsor
- University of LuebeckUniversity, hospital or other
- Collaborators
- University Hospital of Berlin, University Hospital of Cologne, University Hospital Freiburg, University of Giessen, University Hospital Tuebingen
- Study start
- 23 Jun 2021 (actual)
- Primary completion
- 28 Feb 2025 (actual)
- Study completion
- 31 May 2025 (actual)
- First posted
- 24 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Survey on the prevalence of MDRO to monitor the import of MDRO from the community. Rectal swabs will be taken and cultivated. Survey on community-onset and nosocomial bloodstream infections will be documented and strains will be isolated. For each BSI a clinical data set will be obtained (e.g. patient age, gender, date of hospitalization, antibiotic therapy). Genetic analysis of MDRO from the prevalence and BSI study. In a subset of patients the microbiome-resistome interactome will be analysed in more detail. Furthermore, the impact of infection control measures due to the Covid-19 pandemic on nosocomial BSI will be investigated.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- For the prevalence, adult patients admitted to the hosptial within the last 3 days. For BSI surveillance, adult inpatients with at least one blood culture positive for any of the target organisms: Staphylococcus aureus, Enterococcus spp., Escherichia coli, Enterobacter spp., Klebsiella spp., Acinetobacter baumannii, Pseudomonas aeruginosa.
Key inclusion criteria (3 listed)
- at least 18 years old
- informed consent
- inpatient
Key exclusion criteria (3 listed)
- less than 18 years old
- Not capable of giving informed consent
- outpatient
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| rectal swabcollection of rectal swabs | Other | – |
Primary outcome
monitoring of MDRO prevalence
Time frame: at hospital admission
obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure
monitoring of blood stream infections
Time frame: during hospitalization, up to 4 weeks
obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure
integrate novel techniques for microbiome-resistome interaction analysis
Time frame: through study completion, after 4 years
obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
Related trials for MDRO
Active, not recruitingPhase 2
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
Multi-Drug Resistant Organism Colonization
RecruitingPhase 1/2
Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Via Capsules for Intestinal Multidrug-resistant Bacteria Decolonization
Colonization, Asymptomatic
Not yet recruitingPhase 2
A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization
Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA)
RecruitingPhase 2
Further MT for Antibiotic-Resistant Bacterial Colonization
Intestinal Multi-drug Resistant Organism Colonization
Not yet recruitingObservational study
Characterization of the Synergistic Antibacterial Effect of Verapamil on Bacterial Isolates From Cancer Patients
Multi Drug Resistant Organisms, Antibiotic Resistance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of MDRO, run by University of Luebeck at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
monitoring of MDRO prevalence (time frame: at hospital admission). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.